EGFR and non-small cell lung carcinoma: The nanoparticle (cRGD-GIPG) ensures that the treatment is successfully delivered to the EGFR-TKI-resistant NSCLC by inhibiting the activation of the TGF-β/PDLIM5/SMAD resistance pathway and triggering drug-resistant cells to die by mitochondrial apoptosis.